Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel Free LABS Stock Alerts

MediPharm Labs (LABS) Competitors

MediPharm Labs logo
C$0.08 0.00 (0.00%)
As of 09/3/2026 03:33 PM Eastern
Compare

LABS vs. HLS, MGW, I, TGOD, and NINE

Should you buy MediPharm Labs stock or one of its competitors? MediPharm Labs's main competitors and comparable companies include HLS Therapeutics (HLS), Maple Leaf Green World (MGW), Intellipharmaceutics International (I), Green Organic Dutchman (TGOD), and Delta 9 Cannabis (NINE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MediPharm Labs compare to HLS Therapeutics?

MediPharm Labs (TSE:LABS) and HLS Therapeutics (TSE:HLS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

MediPharm Labs has higher earnings, but lower revenue than HLS Therapeutics. HLS Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A
HLS TherapeuticsC$56.24M1.98-C$15.53M-C$0.27N/A

MediPharm Labs has a net margin of -12.00% compared to HLS Therapeutics' net margin of -15.26%. MediPharm Labs' return on equity of -13.79% beat HLS Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-12.00% -13.79% -7.17%
HLS Therapeutics -15.26%-14.39%-2.89%

In the previous week, MediPharm Labs' average media sentiment score of 0.00 equaled HLS Therapeutics'average media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
HLS Therapeutics Neutral

0.3% of MediPharm Labs shares are held by institutional investors. Comparatively, 6.1% of HLS Therapeutics shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Comparatively, 0.4% of HLS Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MediPharm Labs has a beta of -0.564016, suggesting that its share price is 156% less volatile than the broader market. Comparatively, HLS Therapeutics has a beta of -0.484581, suggesting that its share price is 148% less volatile than the broader market.

HLS Therapeutics has a consensus target price of C$8.00, indicating a potential upside of 122.22%. Given HLS Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe HLS Therapeutics is more favorable than MediPharm Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediPharm Labs
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
HLS Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

Summary

HLS Therapeutics beats MediPharm Labs on 9 of the 15 factors compared between the two stocks.

How does MediPharm Labs compare to Maple Leaf Green World?

Maple Leaf Green World (CVE:MGW) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Maple Leaf Green World has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Maple Leaf Green World's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Maple Leaf Green WorldN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

In the previous week, Maple Leaf Green World's average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Maple Leaf Green World Neutral
MediPharm Labs Neutral

Maple Leaf Green World has higher earnings, but lower revenue than MediPharm Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maple Leaf Green WorldN/AN/AN/AN/AN/A
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

0.3% of MediPharm Labs shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Maple Leaf Green World and MediPharm Labs tied by winning 3 of the 6 factors compared between the two stocks.

How does MediPharm Labs compare to Intellipharmaceutics International?

Intellipharmaceutics International (TSE:I) and MediPharm Labs (TSE:LABS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Intellipharmaceutics International has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Intellipharmaceutics International's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellipharmaceutics InternationalN/A N/A N/A
MediPharm Labs -12.00%-13.79%-7.17%

In the previous week, Intellipharmaceutics International's average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score.

Company Overall Sentiment
Intellipharmaceutics International Neutral
MediPharm Labs Neutral

Intellipharmaceutics International has higher earnings, but lower revenue than MediPharm Labs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics InternationalN/AN/AN/AN/AN/A
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Intellipharmaceutics International and MediPharm Labs tied by winning 3 of the 6 factors compared between the two stocks.

How does MediPharm Labs compare to Green Organic Dutchman?

MediPharm Labs (TSE:LABS) and Green Organic Dutchman (TSE:TGOD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

0.3% of MediPharm Labs shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MediPharm Labs has higher revenue and earnings than Green Organic Dutchman. MediPharm Labs is trading at a lower price-to-earnings ratio than Green Organic Dutchman, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A
Green Organic DutchmanC$31.37M0.00-C$137.58M-C$0.26N/A

Green Organic Dutchman has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Green Organic Dutchman's return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-12.00% -13.79% -7.17%
Green Organic Dutchman N/A N/A N/A

In the previous week, MediPharm Labs' average media sentiment score of 0.00 equaled Green Organic Dutchman'saverage media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
Green Organic Dutchman Neutral

Summary

MediPharm Labs beats Green Organic Dutchman on 5 of the 9 factors compared between the two stocks.

How does MediPharm Labs compare to Delta 9 Cannabis?

MediPharm Labs (TSE:LABS) and Delta 9 Cannabis (CVE:NINE) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

0.3% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Delta 9 Cannabis has a net margin of 0.00% compared to MediPharm Labs' net margin of -12.00%. Delta 9 Cannabis' return on equity of 0.00% beat MediPharm Labs' return on equity.

Company Net Margins Return on Equity Return on Assets
MediPharm Labs-12.00% -13.79% -7.17%
Delta 9 Cannabis N/A N/A N/A

In the previous week, Delta 9 Cannabis had 1 more articles in the media than MediPharm Labs. MarketBeat recorded 1 mentions for Delta 9 Cannabis and 0 mentions for MediPharm Labs. MediPharm Labs' average media sentiment score of 0.00 equaled Delta 9 Cannabis'average media sentiment score.

Company Overall Sentiment
MediPharm Labs Neutral
Delta 9 Cannabis Neutral

Delta 9 Cannabis has lower revenue, but higher earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$41.46M0.77-C$12.05M-C$0.01N/A
Delta 9 CannabisC$12.87M6.94C$4.69MC$0.0519.07

Summary

Delta 9 Cannabis beats MediPharm Labs on 8 of the 11 factors compared between the two stocks.

Get MediPharm Labs News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABS vs. The Competition

Export
MetricMediPharm LabsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$32.04MC$12.25BC$7.26BC$12.57B
Dividend YieldN/A2.59%2.53%6.25%
P/E Ratio-7.50787.27273.2939.47
Price / Sales0.77754.88623.679.82
Price / Cash1.3094.8077.8282.29
Price / Book0.9012.3312.924.71
Net Income-C$12.05MC$2.82BC$3.47BC$299.09M
7 Day PerformanceN/A2.60%0.60%-0.31%
1 Month PerformanceN/A6.96%5.72%3.12%
1 Year PerformanceN/A9.45%25.33%28.73%

MediPharm Labs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABS
MediPharm Labs
N/AC$0.08
flat		N/A+7.1%C$32.04MC$41.46MN/A130
HLS
HLS Therapeutics
N/AC$3.75
-4.8%		C$8.00
+113.3%		-33.7%C$116.01MC$56.24MN/A91
MGW
Maple Leaf Green World
N/AC$0.79
+777.8%		N/A+0.0%C$111.69MN/AN/AN/A
I
Intellipharmaceutics International
N/AN/AN/AN/AC$97.40MN/AN/A1,069
TGOD
Green Organic Dutchman
N/AN/AN/AN/AC$89.95MC$31.37MN/A41

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:LABS) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel